Clinical Trials Browser

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT03826043 2025-09-30

THEO

Phase NA Completed

700 enrolled

Neoplasms, Thrombosis, Hemostatic Disorders

NCT05634005 2025-03-06

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

Phase NA Completed

1,543 enrolled

Classical hematologyLymphoid

Afibrinogenemia, Anemia, Lymphoma, Follicular, Thrombocytopenia, Hemostatic Disorders

NCT01183949 2024-08-02

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Phase 1/2 Completed

18 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04517461 2024-02-29

MVL-COAG

Completed

40 enrolled

Head & Neck

Blood Coagulation Disorders, Head and Neck Neoplasms, Intraoperative Complications, Thrombosis, Vitamin K Deficiency, Hemostatic Disorders

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Phase 3 Completed

637 enrolled 15 charts

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT03099031 2019-12-16

PREDICARE

Completed

420 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Digestive System Neoplasms, Intestinal Neoplasms, Leukemia, Lung Neoplasms, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Prostatic Neoplasms, Thromboembolism, Urogenital Neoplasms, Vascular Diseases, Colorectal Neoplasms, Hemostatic Disorders, Venous Thrombosis, Venous Thromboembolism

NCT00079716 2014-12-18

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Phase 1 Completed

44 enrolled

LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Phase 1 Completed

36 enrolled

LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

Clinical Trials

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

THEO

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

MVL-COAG

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

PREDICARE

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma